Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

Hanall News

한올소식 목록
NO 제목 작성일 작성자 조회
34 HanAll Biopharma Appoints David Hernandez as Vice President of Clinical Development Operations 2021-04-13 admin 58
33 HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3 (VELOS-2) Study at a Press Conference 2020-01-28 admin 2763
32 HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease 2019-03-12 admin 3395
31 HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innovation Summit (OIS) in the U.S. 2018-10-29 admin 3017
30 HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND in China 2018-10-01 admin 3066
29 HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaround with Operating Profit of KRW 1.9 billion 2018-08-14 admin 2639
28 HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch of Immunovant 2018-07-11 admin 3706
27 HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World Health Organization (WHO) 2018-06-25 admin 3066
26 HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036 (a new drug for dry eye syndrome) in the U.S. 2018-05-29 admin 2902
25 IM156, a new drug with original technology of HanAll Biopharma, is to be Introduced at the American Society of Clinical Oncology 2018-05-24 admin 2699
현재 페이지1 2 3 4